Global Smoking Cessation Aids Market to reach USD XX billion by 2027. Global Smoking Cessation Aids Market is valued approximately USD XX billion in 2020 and is anticipated to grow with a healthy CAGR of 12.5 % over the forecast period 2021-2027. Smoking cessation aids are de-addiction products designed to help a person quit smoking by replacing the smoking habits with other non-harmful habits such as chewing a nicotine gum and using e cigarettes. The global market for smoking cessation aids is fueled by the high cigarette smoking population around the world. According to Word Health Organization's 2021 factsheet, over 1.3 billion people consume tobacco and most of the consumption comes from smoking. The huge smoking population also feeds the demand for products that help quit smoking.
In many countries, governments and several non-government bodies are running anti-smoking campaigns which also fuels the growth of Smoking Cessation Aids market. In 2017, FDA launched a smoking cessation awareness campaign in USA, with a motive of educating cigarette smokers about the ways of quitting smoking. Australia government also runs a National Tobacco campaign since 1997, aimed at reducing smokers in the country through TV advertisements, social media content and de-addiction camps.
However, rising costs of development of Nicotine replacement products and therapies can hamper the market growth in the forecast period of 2021-2027. Nevertheless, with rising awareness about the lethal effects of smoking and rising trend of e-cigarettes, Smoking Cessation Aids Market is likely to increase the market growth during the forecast period.
Among regions including Asia Pacific, North America, Europe, Latin America and Rest of the World, regional analysis demonstrates that Asia Pacific is the most significant player across the world in terms of market share owing to Asia being world's largest tobacco consumer, and rapidly developing health infrastructure in China and India. Asia Pacific is also anticipated to exhibit the highest CAGR over the forecast period 2021-2027. Factors such as rising awareness about de-addiction products, rising disposable income and extensive government programs would create lucrative growth prospects for the Smoking Cessation Aids Market across Asia Pacific.
Major market player included in this report are:
NJOY
Pfizer Inc.
GlaxoSmithKline Plc
F. Hoffmann-La Roche AG
Novartis AG
Johnson and Johnson
Bayer AG
Cipla Ltd
Takeda Pharmaceutical Co. Ltd.
Dr. Reddy's Laboratories
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Product:
Nicotine Replacement Therapy
NRT Gum
NRT Lozenges
NRT Inhalers
NRT Patches
Sprays
Drugs
Electronic Cigarettes
Others
By End User:
Hospital Pharmacies
Online Channel
Retail Pharmacies
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World
Furthermore, years considered for the study are as follows:
Historical year - 2018, 2019
Base year - 2020
Forecast period - 2021 to 2027
Target Audience of the Global Smoking Cessation Aids Market in Market Study:
Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors
